Acute myeloid leukemia in the elderly: assessment of multidrug resistance (MDR1) and cytogenetics distinguishes biologic subgroups with remarkably distinct responses to standard chemotherapy. A Southwest Oncology Group study - PubMed (original) (raw)
Clinical Trial
. 1997 May 1;89(9):3323-9.
Affiliations
- PMID: 9129038
Free article
Clinical Trial
Acute myeloid leukemia in the elderly: assessment of multidrug resistance (MDR1) and cytogenetics distinguishes biologic subgroups with remarkably distinct responses to standard chemotherapy. A Southwest Oncology Group study
C P Leith et al. Blood. 1997.
Free article
Abstract
Compared with younger patients, elderly patients with acute myeloid leukemia (AML) respond poorly to conventional chemotherapy. To determine if this poor response is due to differences in the biologic characteristics of AML in the elderly, we studied 211 patients (161 de novo, 50 secondary AML) over 55 years of age (median, 68 years) registered to a single clinical trial for previously untreated AML (SWOG 9031, Phase III randomized trial of standard dose cytosine arabinoside and daunomycin + rhG-CSF). Pretreatment leukemic blasts were karyotyped and were also analyzed for intrinsic drug resistance by quantitating expression of the multidrug resistance glycoprotein MDR1 and functional drug efflux using sensitive flow cytometric techniques. Results were correlated with clinical variables and outcome. These elderly AML patients had a high frequency of unfavorable cytogenetics (32%), MDR1 protein expression (71%), and functional drug efflux (58%); each of these factors occurred at high frequencies in both de novo and secondary AML patients and was associated with a significantly poorer complete remission (CR) rate. In multivariate analysis, secondary AML (P = .0035), unfavorable cytogenetics (P = .0031), and MDR1 (P = .0041) were each significantly and independently associated with lower CR rates. Resistant disease was associated with unfavorable cytogenetics (P = .017) and MDR1 expression (P = .0007). Strikingly, elderly MDR1(-) de novo AML patients with favorable/intermediate cytogenetics had a CR rate of 81%; with increasing MDR1 expression, CR rate decreased in this cytogenetic group. MDR1(+) secondary AML patients with unfavorable cytogenetics had a CR rate of only 12%. Thus, AML in the elderly is associated with an increased frequency of unfavorable cytogenetics and MDR1 expression, both of which independently contribute to poor outcomes. The high frequencies of these features in both de novo and secondary elderly AML patients suggest a common biologic mechanism for these leukemias distinct from that in younger patients. Investigation of biologic parameters at diagnosis in AML in the elderly may help identify patients with a high likelihood of achieving CR with conventional regimens, as well as those who may require alternate regimens designed to overcome therapy resistance.
Similar articles
- Frequency and clinical significance of the expression of the multidrug resistance proteins MDR1/P-glycoprotein, MRP1, and LRP in acute myeloid leukemia: a Southwest Oncology Group Study.
Leith CP, Kopecky KJ, Chen IM, Eijdems L, Slovak ML, McConnell TS, Head DR, Weick J, Grever MR, Appelbaum FR, Willman CL. Leith CP, et al. Blood. 1999 Aug 1;94(3):1086-99. Blood. 1999. PMID: 10419902 Clinical Trial. - Intensive chemotherapy with idarubicin, cytosine arabinoside, and granulocyte colony-stimulating factor (G-CSF) in patients with secondary and therapy-related acute myelogenous leukemia. Club de Réflexion en Hématologie.
Gardin C, Chaibi P, de Revel T, Rousselot P, Turlure P, Micléa JM, Nédellec G, Dombret H. Gardin C, et al. Leukemia. 1997 Jan;11(1):16-21. doi: 10.1038/sj.leu.2400536. Leukemia. 1997. PMID: 9001413 Clinical Trial. - Expression of MDR1 by normal bone marrow cells and its implication for leukemic hematopoiesis.
Drach J, Zhao S, Drach D, Körbling M, Engel H, Andreeff M. Drach J, et al. Leuk Lymphoma. 1995 Feb;16(5-6):419-24. doi: 10.3109/10428199509054428. Leuk Lymphoma. 1995. PMID: 7540457 Review.
Cited by
- Treatment of Acute Myeloid Leukemia in Older Adults.
Alsouqi A, Geramita E, Im A. Alsouqi A, et al. Cancers (Basel). 2023 Nov 14;15(22):5409. doi: 10.3390/cancers15225409. Cancers (Basel). 2023. PMID: 38001669 Free PMC article. Review. - Role of Intracellular Drug Disposition in the Response of Acute Myeloid Leukemia to Cytarabine and Idarubicin Induction Chemotherapy.
Rodríguez-Macías G, Briz O, Cives-Losada C, Chillón MC, Martínez-Laperche C, Martínez-Arranz I, Buño I, González-Díaz M, Díez-Martín JL, Marin JJG, Macias RIR. Rodríguez-Macías G, et al. Cancers (Basel). 2023 Jun 11;15(12):3145. doi: 10.3390/cancers15123145. Cancers (Basel). 2023. PMID: 37370755 Free PMC article. - Identification and validation of a 7-genes prognostic signature for adult acute myeloid leukemia based on aging-related genes.
Ke P, Zhu Q, Xu T, Yang X, Wang Y, Qiu H, Wu D, Bao X, Chen S. Ke P, et al. Aging (Albany NY). 2023 Jun 26;15(12):5826-5853. doi: 10.18632/aging.204843. Epub 2023 Jun 26. Aging (Albany NY). 2023. PMID: 37367950 Free PMC article. - The influence of BCL2, BAX, and ABCB1 gene expression on prognosis of adult de novo acute myeloid leukemia with normal karyotype patients.
Pravdic Z, Vukovic NS, Gasic V, Marjanovic I, Karan-Djurasevic T, Pavlovic S, Tosic N. Pravdic Z, et al. Radiol Oncol. 2023 Apr 20;57(2):239-248. doi: 10.2478/raon-2023-0017. eCollection 2023 Jun 1. Radiol Oncol. 2023. PMID: 37078709 Free PMC article. - Recent advances in targeted therapies in acute myeloid leukemia.
Bhansali RS, Pratz KW, Lai C. Bhansali RS, et al. J Hematol Oncol. 2023 Mar 25;16(1):29. doi: 10.1186/s13045-023-01424-6. J Hematol Oncol. 2023. PMID: 36966300 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical